Journey Medical Corp (DERM) Stock Price, Quote & News

Company Profile

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 480 434 6670

Website: journeymedicalcorp.com

Address:

9237 East Via de Ventura Boulevard, Suite 105, Scottsdale, United States

buymoremakemore Mar. 21 at 7:35 PM

$DERM We are trending!

0 · Reply

hofno2003 Mar. 21 at 7:24 PM

$DERM $MIST $TNXP 3 companies, 3 best in class products in early launch phase.

2 · Reply

hofno2003 Mar. 21 at 7:12 PM

$DERM We are actually at 4K Rx/week, annualized a run rate of about 200K Rx or $100M+

1 · Reply

hofno2003 Mar. 21 at 6:20 PM

$DERM

0 · Reply

buymoremakemore Mar. 20 at 5:40 PM

$DERM There is growing evidence that daily Emrosi use leads to significant improvement in rosacea. However when stopping Emrosi, rosacea rebounds. Emrosi is THE effective maintenance therapy that dermatologists for DECADES have searched for. Maintenance = more money for Journey!

0 · Reply

Tomasini Mar. 20 at 1:38 PM

$DERM not sure whats going on here. keep buying i guess

1 · Reply

Tomasini Mar. 19 at 3:58 PM

$DERM same short trading partern all week

0 · Reply

Tomasini Mar. 19 at 3:44 PM

$DERM company indicates total market forrosacea treatment was $1.2 billion in 2024 with Oracea around $200 million and falling due to generics and over the counter stuff. so what then is the TAM for Emrosi? maybe $150 million /year which gets us maybe $4/share earnings. conservative p/e of 5 seems reasonable so maximum share price is &20. probably 3 years out.

1 · Reply

buymoremakemore Mar. 19 at 1:26 AM

$DERM Accutane generic erosion 2025 vs 2024 definitely was significant, but Q to Q hasn’t been that bad in 2025. Ittl be interesting what their guidance will be. Either way we only care about accutane for a few more quarters as Emrosi launch gets underway. 18.86M is revenue estimate. For Q4, I think we get somewhere between 19M - 21M quarterly revenue after subtracting the 10K values from 9 month values in Q3 10Q. My estimate accounts for Qbrexza seasonality and may be a few $100,000 on conservative side for the franchise products. So I think we are in for an earnings beat! We just need to be patient a few more quarters, definitely will buy dip if we head back to $5 or $6. But I think we are heading back to $8 - $10+.

1 · Reply

FinSUN Mar. 18 at 10:06 PM

$DERM zero trust. Buying back opportunistically only in area $5, otherwise I can live without it.

1 · Reply

Journey Medical Corporation to Announce Year End 2025 Financial Results on March 25, 2026

FBIO

Jan 22, 2026, 8:43 PM EST - 2 months ago

Journey Medical: Emrosi Is Winning, But The Stock Hasn't Noticed

Dec 10, 2025, 8:30 AM EST - 3 months ago

Journey Medical Corporation Announces Publication of Clinical Trial Results Assessing the Impact of Emrosi™ (DFD-29) on Microbial Flora of Healthy Adults in the Journal of Drugs in Dermatology

FBIO

Nov 12, 2025, 7:31 PM EST - 4 months ago

Journey Medical Corporation (DERM) Q3 2025 Earnings Call Transcript

Nov 12, 2025, 4:01 PM EST - 4 months ago

Journey Medical Corporation Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

FBIO

Nov 5, 2025, 8:30 AM EST - 4 months ago

Journey Medical Corporation to Announce Third Quarter 2025 Financial Results on November 12, 2025

FBIO

Oct 24, 2025, 8:30 AM EDT - 5 months ago

Journey Medical Corporation Reports Combined Emrosi™ (DFD-29) Phase 3 Clinical Trial Efficacy Data Analysis Presented at the 2025 Fall Clinical Dermatology Conference

FBIO

Oct 8, 2025, 8:30 AM EDT - 5 months ago

Journey Medical Corporation to Participate in October 2025 Investor Conferences

FBIO

Sep 6, 2025, 8:44 AM EDT - 7 months ago

Journey Medical: EMROSI's Ramp Puts Profitability On The Horizon

Sep 3, 2025, 8:30 AM EDT - 7 months ago

Journey Medical Corporation to Participate in September 2025 Investor Conferences

FBIO

Aug 18, 2025, 8:30 AM EDT - 7 months ago

Journey Medical Corporation to Present at the Emerging Growth Conference

FBIO

Aug 13, 2025, 8:35 AM EDT - 7 months ago

CoreWeave, CAVA Group, Journey Medical And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

CAVA CRWV

Aug 12, 2025, 6:42 PM EDT - 7 months ago

Journey Medical Corporation (DERM) Q2 2025 Earnings Call Transcript

Aug 12, 2025, 4:01 PM EDT - 7 months ago

Journey Medical Corporation Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

FBIO

Aug 7, 2025, 8:30 AM EDT - 8 months ago

Journey Medical Corporation to Ring Nasdaq Stock Market Closing Bell on August 11

FBIO

Aug 5, 2025, 4:01 PM EDT - 8 months ago

Journey Medical Corporation to Announce Second Quarter 2025 Financial Results on August 12, 2025

FBIO

Jul 14, 2025, 8:30 AM EDT - 8 months ago

Journey Medical Corporation Announces Expanded Payer Coverage for Emrosi™

FBIO

Jun 24, 2025, 8:30 AM EDT - 9 months ago

Journey Medical to Join Russell 2000® and Russell 3000® Indexes

FBIO

Jun 20, 2025, 8:30 AM EDT - 9 months ago

Journey Medical Corporation Announces Emrosi™ Data Analysis to be Presented at the Society of Dermatology Physician Associates (SDPA) 2025 Annual Summer Dermatology Conference

FBIO

Jun 9, 2025, 8:30 AM EDT - 10 months ago

Journey Medical Corporation Announces Emrosi™ Featured on “The Balancing Act” Airing on Lifetime TV

FBIO

May 14, 2025, 7:08 PM EDT - 11 months ago

Journey Medical Corporation (DERM) Q1 2025 Earnings Call Transcript

May 14, 2025, 4:01 PM EDT - 11 months ago

Journey Medical Corporation Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

FBIO

May 7, 2025, 4:01 PM EDT - 11 months ago

Journey Medical Corporation to Announce First Quarter 2025 Financial Results on May 14, 2025

FBIO

Apr 7, 2025, 11:23 AM EDT - 1 year ago

Top 3 Health Care Stocks That May Crash In Q2

ALMS CMRX

Apr 1, 2025, 4:01 PM EDT - 1 year ago

Journey Medical Corporation Appoints Ramsey Alloush as Chief Operating Officer

FBIO

Mar 26, 2025, 7:10 PM EDT - 1 year ago

Journey Medical Corporation (DERM) Q4 2024 Earnings Call Transcript

Mar 26, 2025, 4:01 PM EDT - 1 year ago

Journey Medical Corporation Reports Full-Year 2024 Financial Results and Recent Corporate Highlights

FBIO

Mar 24, 2025, 8:30 AM EDT - 1 year ago

Journey Medical Corporation Launches Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) for the Treatment of Rosacea

FBIO

Mar 19, 2025, 4:01 PM EDT - 1 year ago

Journey Medical Corporation to Announce Year End 2024 Financial Results on March 26, 2025

FBIO

Mar 12, 2025, 8:30 AM EDT - 1 year ago

Journey Medical Corporation to Participate in the 37th Annual ROTH Conference

FBIO

Mar 5, 2025, 4:01 PM EST - 1 year ago

Journey Medical Corporation Announces Publication in the Journal of the American Medical Association - Dermatology of the Phase 3 Clinical Trial Results of Emrosi™ (DFD-29) to Treat Rosacea

FBIO

Mar 4, 2025, 4:01 PM EST - 1 year ago

Journey Medical Corporation to Exhibit at the 2025 American Academy of Dermatology Annual Meeting in Orlando, Florida

FBIO

Feb 5, 2025, 8:30 AM EST - 1 year ago

Stock Picks From Seeking Alpha's January 2025 New Analysts

ACIW ASML AUNA BE BITF BRAG BSY

Jan 30, 2025, 9:18 AM EST - 1 year ago

Journey Medical Corporation: Emrosi's Launch Could Be A Turning Point

Jan 23, 2025, 8:30 AM EST - 1 year ago

Journey Medical Corporation to Host Conference Call to Discuss U.S. Commercial Launch Plan for Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea

FBIO

Nov 12, 2024, 4:01 PM EST - 1 year ago

Journey Medical Corporation Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

FBIO

Nov 4, 2024, 7:00 AM EST - 1 year ago

Journey Medical Corporation Announces U.S. FDA Approval of Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea

FBIO

Oct 25, 2024, 8:30 AM EDT - 1 year ago

Journey Medical Corporation Announces DFD-29 Data Presented at 44th Fall Clinical Dermatology Conference

FBIO

Oct 3, 2024, 8:30 AM EDT - 1 year ago

Journey Medical Corporation to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

FBIO

Sep 9, 2024, 8:30 AM EDT - 1 year ago

Journey Medical Corporation to Participate in the Lake Street Capital Markets 8th Annual Best Ideas Growth (BIG) Conference

FBIO

Sep 4, 2024, 8:15 AM EDT - 1 year ago

Journey Medical Corporation to Present at the H.C. Wainwright 26th Annual Global Investment Conference

FBIO

Aug 12, 2024, 7:37 PM EDT - 1 year ago

Journey Medical Corporation (DERM) Q2 2024 Earnings Call Transcript

Aug 12, 2024, 4:01 PM EDT - 1 year ago

Journey Medical Corporation Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

FBIO

Aug 6, 2024, 4:01 PM EDT - 1 year ago

Journey Medical Corporation to Announce Second Quarter 2024 Financial Results on August 12, 2024

FBIO

Jul 11, 2024, 4:05 PM EDT - 1 year ago

Journey Medical Corporation Appoints Michael C. Pearce to Board of Directors

FBIO

May 15, 2024, 4:01 PM EDT - 2 years ago

Journey Medical Corporation to Participate in the Alliance Global Partners' (A.G.P.) Virtual Healthcare Company Showcase

FBIO

May 13, 2024, 10:43 PM EDT - 2 years ago

Journey Medical Corporation (DERM) Q1 2024 Earnings Call Transcript

May 13, 2024, 4:01 PM EDT - 2 years ago

Journey Medical Corporation Reports First Quarter 2024 Financial Results and Recent Corporate Highlights

FBIO

May 7, 2024, 8:30 AM EDT - 2 years ago

Journey Medical Corporation to Announce First Quarter 2024 Financial Results on May 13, 2024

FBIO

May 1, 2024, 4:01 PM EDT - 2 years ago

Journey Medical Corporation Appoints Joseph Benesch as Chief Financial Officer

FBIO

buymoremakemore Mar. 21 at 7:35 PM

$DERM We are trending!

0 · Reply

hofno2003 Mar. 21 at 7:24 PM

$DERM $MIST $TNXP 3 companies, 3 best in class products in early launch phase.

2 · Reply

hofno2003 Mar. 21 at 7:12 PM

$DERM We are actually at 4K Rx/week, annualized a run rate of about 200K Rx or $100M+

1 · Reply

hofno2003 Mar. 21 at 6:20 PM

$DERM

0 · Reply

buymoremakemore Mar. 20 at 5:40 PM

0 · Reply

Tomasini Mar. 20 at 1:38 PM

$DERM not sure whats going on here. keep buying i guess

1 · Reply

Tomasini Mar. 19 at 3:58 PM

$DERM same short trading partern all week

0 · Reply

Tomasini Mar. 19 at 3:44 PM

1 · Reply

buymoremakemore Mar. 19 at 1:26 AM

1 · Reply

FinSUN Mar. 18 at 10:06 PM

$DERM zero trust. Buying back opportunistically only in area $5, otherwise I can live without it.

1 · Reply

buymoremakemore Mar. 18 at 7:02 PM

$DERM The prescriptions are going to be off the charts for Q4 ER!!! Revenue will follow. Dermatologists are going to bat for patients for them to get coverage. When patients look good, they look good. Insurance companies will pay. This stands out compared to drugs that are just alternate MOAs of the same molecule like Neffy. Neffy isn't 30% better than an epipen!!

0 · Reply

Tomasini Mar. 18 at 4:45 PM

$DERM notice the short trading patternlast few days. 7.7 to 7.25 range

0 · Reply

Tomasini Mar. 18 at 1:55 PM

$DERM any kind if good news next week on emrosi should push us to 10

0 · Reply

Sawnchey Mar. 18 at 12:59 PM

$FBIO $DERM Good to see only 1 week until DERM results. If Emrosi scripts have grown even modestly, this could tip the company into profitability. This would be big news for both companies for a few reasons 1. It would demonstrate to potential partners that licensing Emrosi could be a profitable venture, opening up further avenues for growth. 2. As much as I like DERM, their valuation is mostly underpinned by sales with a less-than-perfect cash balance. Getting some organic income would really help with shoring up the balance sheet and hopefully attract more institutional investment. 3. For Fortress, this would further validate the business model and help smooth out those 10-k numbers ahead of the PRV proceeds hitting the books in Q1 reporting.

2 · Reply

JuggernautRaider Mar. 17 at 8:54 PM

$DERM appreciate the heads up @hofno2003 . I need to do a deep dive on Emrosi. This may join my Top Ten Biotech list along with $ALT $IMRX and of course $TNXP

0 · Reply

Tomasini Mar. 17 at 2:18 PM

$DERM my morning dump has more volume than this turd

0 · Reply

Tomasini Mar. 16 at 6:16 PM

$DERM definitely a short pattern

1 · Reply

buymoremakemore Mar. 15 at 7:24 PM

$DERM Almost daily there is more positive news on Emrosi about its effectiveness. It seems that people have tried many things that did not work and now they've found Emrosi. What I've seen is that people will need to keep taking Emrosi for their skin to continue to be clear, which means more money for Journey. The continued elevated prescription volume is an indication of effectiveness and demand, which historically is a catalyst for insurance companies to cover a drug more favorably. It's not too late to get buy in. https://www.reddit.com/r/perioraldermatitis/comments/1rt2gbx/has_anyone_had_success_with_emrosi_minocycline/

1 · Reply

buymoremakemore Mar. 15 at 3:47 PM

$DERM This woman’s dermatologist was able to get Emrosi covered by insurance. It’s only inevitable for more people to be covered for emrosi by insurance. As the empirical evidence of its superiority is spread, dermatologists will overwhelm insurance companies with claims DEMANDING Emrosi be covered. It has to been on the market for a year. It’s coming.

0 · Reply

buymoremakemore Mar. 14 at 12:46 AM

$DERM The prescriptions and results are coming in. Steal at this price.

0 · Reply

Tomasini Mar. 13 at 6:27 PM

$DERM holy shit. loading at 7.20 some low volume shorting going on

0 · Reply

Tomasini Mar. 13 at 4:23 PM

$DERM time to buy at 7.50. dirt cheap

0 · Reply

Market Cap	220.49M
Revenue (ttm)	56.13M
Net Income (ttm)	-14.67M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	25.74
Profit Margin	-26.14%
Debt to Equity Ratio	0.97

Volume	998,000
Avg Vol	140,966
Day's Range	N/A - N/A
Shares Out	33.26M
Stochastic %K	1%
Beta	0.81
Analysts	Strong Sell
Price Target	$13.50